Abstract: The present invention relates to nucleic acid molecules simultaneously inhibiting the expression of a C-MET gene and a PD-L1 gene, and an anti-cancer pharmaceutical composition comprising same. All of the bispecific nucleic acid molecules of the present invention, designed so that the sense strand inhibits the expression of PD-L1 gene and the antisense strand inhibits the expression of c-MET gene, simultaneously inhibit the expression of a c-MET gene and a PD-L1 gene when actually applied as siRNA or shRNA to various cancer cells and remarkably inhibit the expression of both genes even when applied as shRNA to viruses, and thus are usable as an anti-cancer composition or an anti-cancer adjuvant for a variety of carcinomas, can be locally delivered, and having excellent selectivity.

Abstract: Disclosed is a method comprising extracting a gene sequence of a first gene from a first database in response to receiving a user's input, generating segmented sequences on the basis of the reverse complementary sequence of the gene sequence of the first gene, identifying, based on comparison of the segmented sequences with gene sequences of a second database, at least one matched sequence corresponding to at least one segmented sequence of the segmented sequences.

Abstract: The present invention relates to a modified hTERT promoter for regulating cancer cell-specific gene expression and an oncolytic adenovirus including the same. The modified hTERT promoter of the present invention increases the cancer-specific transcriptional activity of a target gene compared to the case where a wild-type hTERT promoter is used, and when the modified hTERT promoter is used for an oncolytic adenovirus, the tumor-killing effect is excellent compared to the case where an adenovirus is prepared using the wild-type hTERT promoter.

Abstract: The present invention relates to an anti-tumor adenovirus and an anticancer composition comprising same. Double-stranded siRNA of the present invention simultaneously inhibits the expression of a first nucleic acid and a second nucleic acid, thus promoting the death of cancer cells, exhibits more remarkable anticancer activity as compared to co-treatment of respective siRNAs, has a synergistic effect of improving cancer cell death in combined treatment with an anticancer agent. The adenovirus comprising a shRNA-encoding expression cassette expressing the double-stranded siRNA, and a hTERT promoter evades immune responses in the body and is specifically delivered to cancer cells, thus having a systemic therapeutic effect, can be locally delivered, has excellent selectivity, and exhibits a significant anticancer effect even in minimally invasive treatment, and thus, the adenovirus can be effectively used as an anticancer composition or an anticancer adjuvant in various carcinomas.

Abstract: The present invention relates to a nucleic acid molecule simultaneously inhibiting the expression of mTOR gene and STAT3 gene, and an anticancer pharmaceutical composition comprising the same. More specifically, base-paired siRNA or shRNA of the present invention, designed to simultaneously inhibit the expression of cancer-related mTOR gene and STAT3 gene in order to surmount the problem that siRNA or shRNA does not achieve high therapeutic effects due to the target specificity thereof, has the effect of promoting the death of cancer cells. In addition, the nucleic acid has the effect of synergistically enhancing the apoptosis of cancer cells when used in combination with an anticancer agent, finding useful applications as an anticancer composition or anticancer aid against various carcinomas.

Abstract: The present invention relates to a nucleic acid molecule simultaneously inhibiting the expression of mTOR gene and STAT3 gene, and an anticancer pharmaceutical composition comprising the same. More specifically, base-paired siRNA or shRNA of the present invention, designed to simultaneously inhibit the expression of cancer-related mTOR gene and STAT3 gene in order to surmount the problem that siRNA or shRNA does not achieve high therapeutic effects due to the target specificity thereof, has the effect of promoting the death of cancer cells. In addition, the nucleic acid has the effect of synergistically enhancing the apoptosis of cancer cells when used in combination with an anticancer agent, finding useful applications as an anticancer composition or anticancer aid against various carcinomas.

Abstract: The present invention relates to nucleic acid molecules that simultaneously inhibit the expression of AR gene and mTOR gene, wherein the double-stranded siRNA and shRNA of the present invention were designed to simultaneously inhibit the expression of the AR gene and the mTOR gene which are associated with cancer. The double-stranded siRNA and shRNA of the present invention promote cancer cell death and synergistically enhance cancer cell death in combination with an anticancer agent, so that various types of cancer may be effectively prevented and treated.

Abstract: The present invention relates to a nucleic acid molecule simultaneously inhibiting the expression of mTOR gene and STAT3 gene, and an anticancer pharmaceutical composition comprising the same. More specifically, base-paired siRNA or shRNA of the present invention, designed to simultaneously inhibit the expression of cancer-related mTOR gene and STAT3 gene in order to surmount the problem that siRNA or shRNA does not achieve high therapeutic effects due to the target specificity thereof, has the effect of promoting the death of cancer cells. In addition, the nucleic acid has the effect of synergistically enhancing the apoptosis of cancer cells when used in combination with an anticancer agent, finding useful applications as an anticancer composition or anticancer aid against various carcinomas.

Abstract: The present invention relates to nucleic acid molecules that simultaneously inhibit the expression of AR gene and mTOR gene, wherein the double-stranded siRNA and shRNA of the present invention were designed to simultaneously inhibit the expression of the AR gene and the mTOR gene which are associated with cancer. The double-stranded siRNA and shRNA of the present invention promote cancer cell death and synergistically enhance cancer cell death in combination with an anticancer agent, so that various types of cancer may be effectively prevented and treated.

Abstract: The present invention relates to a nucleic acid molecule simultaneously inhibiting the expression of mTOR gene and STAT3 gene, and an anticancer pharmaceutical composition comprising the same. More specifically, base-paired siRNA or shRNA of the present invention, designed to simultaneously inhibit the expression of cancer-related mTOR gene and STAT3 gene in order to surmount the problem that siRNA or shRNA does not achieve high therapeutic effects due to the target specificity thereof, has the effect of promoting the death of cancer cells. In addition, the nucleic acid has the effect of synergistically enhancing the apoptosis of cancer cells when used in combination with an anticancer agent, finding useful applications as an anticancer composition or anticancer aid against various carcinomas.